Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

US12415843B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• John M. Timmerman · Los Angeles, US
• Reiko King · Los Angeles, US
• Patricia A. Young · Madison, US
• Alex Vasuthasawat · Los Angeles, US
• Kham M. Trinh · Alhambra, US
• Sherie L. Morrison · Los Angeles, US

Key dates

• Filing date: Mar 18, 2019
• Grant date: Sep 16, 2025
• Expiry date: Dec 4, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In various embodiments methods are provided that involve the use of antibody-interferon (Ab-IFN) fusion proteins to boost the cancer-fighting capacity of adoptive T cell therapies (ACT), including any T cells that are manipulated and grown outside the body, then returned to the patient with the goal of having the infused T cells home to sites of tumor and destroy the cancer in an immunologic attack. Illustrative, but non-limiting, adoptive T cell therapies include chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), virus-specific T cells, and T cell receptor transgenic T cells.